China National Medicines (SHSE:600511) Retained Earnings: ¥15,059 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600511 China National Medicines Corp Ltd SHSE:600511
90 GF Score
Price ¥26.77
GF Value ¥32.09
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is China National Medicines Retained Earnings?

China National Medicines SHSE:600511 -0.04% 90 Retained Earnings is ¥15,059 Mil as of Jun. 2026. GuruFocus rates SHSE:600511 with a GF Score™ of 90/100 and a GF Value™ of ¥32.09 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. China National Medicines's retained earnings for the quarter that ended in Jun. 2026 was ¥15,059 Mil.

China National Medicines's quarterly retained earnings increased from Dec. 2025 (¥14,783 Mil) to Mar. 2026 (¥15,257 Mil) but then declined from Mar. 2026 (¥15,257 Mil) to Jun. 2026 (¥15,059 Mil).

China National Medicines's annual retained earnings increased from Dec. 2023 (¥12,034 Mil) to Dec. 2024 (¥13,390 Mil) and increased from Dec. 2024 (¥13,390 Mil) to Dec. 2025 (¥14,783 Mil).


China National Medicines  (SHSE:600511) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


China National Medicines Retained Earnings Historical Data

* Premium members only.

The historical data trend for China National Medicines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China National Medicines Retained Earnings Chart

China National Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,044.13 10,479.85 12,034.40 13,390.18 14,783.17

China National Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,735.12 14,278.84 14,783.17 15,257.43 15,059.34
SHSE:600511
90GF Score
China National Medicines Corp Ltd SHSE:600511
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China National Medicines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of ¥15,059 Mil mean?
China National Medicines (SHSE:600511) has a Retained Earnings of ¥15,059 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on China National Medicines and its competitors.
Is China National Medicines' Retained Earnings too high?
China National Medicines' current Retained Earnings is ¥15,059 Mil. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Retained Earnings compare to MCK and COR?
China National Medicines' Retained Earnings of ¥15,059 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Distribution company?
A good Retained Earnings depends on the Medical Distribution industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on China National Medicines and its competitors. China National Medicines's current Retained Earnings is ¥15,059 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Retained Earnings is ¥15,059 Mil. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Retained Earnings is ¥15,059 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China National Medicines (SHSE:600511) Overvalued in 2026?

Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued. The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09. GuruFocus considers China National Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:600511:

  • Retained Earnings: ¥15,059 Mil
  • GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China National Medicines Business Description

Address No. 8, Xibinhe Road, Floor 6-9, West Tower, 7th Floor, Yongdingmen, Dongcheng District, Beijing, CHN, 100077
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score

Get the complete analysis for SHSE:600511

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥26.77
Price
¥32.09
GF Value